



eChinaHealth JPMorgan Week Pitch Day

eChinaHealth teams up with MORE Health, CABS, MSQ Ventures and ANM Partners, we bring highly selective biopharma and medtech innovations from US, Europe and Asia to you on Jan. 9th all-day Pitch Day.

For any other requests, or you have awesome projects, please contact bp@eChinaHealth.com or learn more at www.eChinaHealth.com.

Selected Pitch Day Projects

Presentation Time: 9:15-9:30

No. A1903	Allogeneic Human Bone Marrow-Derived Clonal Mesenchymal Stem Cells (hBMcMSC) Programs		
Country	Korea	Project Classification	Biotechnology
Project Phase	Phase II		
Financial Funding Strategic Request	Licensing China and global rights; Financial funding: C round		

Presentation Time: 9:30-9:45

No. A1901	Sub-retinal Miniature Photovoltaic Wireless Implant System		
Country	France	Project Classification	Medical Devices
Project Phase	Corresponds to phase I/II for biotechnology product.		
Financial Funding Strategic Request	Seeking to China and US partners.		

Presentation Time: 9:45-10:00

No. A1902	Monoclonal Antibody/Orphan Drug		
Country	France	Project Classification	Rare disease
Project Phase	EAP Phase III		
Financial Funding Strategic Request	Licensing China and global rights; Financial funding: B/ Pre-IPO		

Presentation Time: 10:00-10:15

No. A1904	First-in-class Antibodies Drug		
Country	France	Project Classification	Biotechnology
Project Phase	Phase II		
Financial Funding Strategic Request	Licensing China and global rights; Financial funding: C round		

Presentation Time: 10:15-10:30

No. E1901	AI Instant Diagnosis (POCT) System		
Country	US	Project Classification	AI Medical Devices
Project Phase	US on market, China NMPA submission, expect approval Q1 2019.		
Financial Funding Strategic Request	A-Round Financing		

Presentation Time: 10:30-10:45

No. E1905	Multiple Innovative Oncology Programs		
Country	US	Project Classification	Oncology Therapeutics
Project Phase	IND-ready		
Financial Funding Strategic Request	Looking for strategic partners to license out China or global rights		

Presentation Time: 10:45-11:00

No. E1911	Algorithms as companion diagnostics		
Country	US	Project Classification	Pharmaceutical
Project Phase	One marketed product, one product partnered with Big pharma in Ph2, late stage negotiations for in-licensing two Ph3 assets		
Financial Funding Strategic Request	Seeking Series A		

Presentation Time: 11:00-11:15

No. E1907	CAR-T		
Country	China	Project Classification	Biotechnology
Project Phase	Phase 1		
Financial Funding Strategic Request	B-Round Financing		

Presentation Time: 11:15-11:30

No. E1906	Overcoming Barriers of Drug Delivery to Solid Tumors		
Country	US	Project Classification	Biopharmaceuticals
Project Phase	Phase I		
Financial Funding Strategic Request	A-Round Financing and Licensing China Rights		

Presentation Time: 11:30-11:45

No. E1903	Therapeutic Antibody Drug		
Country	China	Project Classification	Biopharmaceuticals
Project Phase	Developed Therapeutic Antibody Discovery Platform.		
Financial Funding Strategic Request	B-Round Financing		

Presentation Time: 11:45-12:00

No. E1914

Presentation Time: 12:00-12:15

No. E1915	Regenerative medicine for reversing bone loss		
Country	Canada	Project Classification	Biopharmaceuticals
Project Phase	Pre-Clinical		
Financial Funding Strategic Request	Financial funding: US \$1.5M		

Presentation Time: 12:45-1:00pm

No. E1913	Bringing Biomarkers and CDx to Precision Medicine			
Country	China	Project Classification	Biotechnology, Medical Devices, In Vitro Diagnostics	
Project Phase	On market			
Financial Funding Strategic Request	B-Round Financing. Seeking like-minded pharmaceutical partners to work together to develop companion diagnostics (CDx) and patients stratification services. Looking for Clinical Laboratory Improvement Amendments (CLIA) LAB ' s acquisition, diagnostic technology's introduction and co-development.			

Presentation Time: 1:00-1:15pm

No. E1910	Transforming the Treatment of Sleep Apnea		
Country	US	Project Classification	Electronic Medical Device
Project Phase	FDA-approved		
Financial Funding Strategic Request	Commercialization Financing. Distribution partners set for US and Japan, still open for proposals in China.		

Presentation Time: 1:15-1:30pm

No. E1912	Smarter Anesthesia Devices		
Country	US	Project Classification	Medical Devices
Project Phase	On market		
Financial Funding Strategic Request	B/C-Round Financing and Licensing China and global rights; M&A, Divergence, Others.		

Presentation Time: 1:30-1:45pm

No. E1909	A Digital Therapeutic Solution that targets Digital Eye Strain (DES)		
Country	US	Project Classification	Digital Therapeutics
Project Phase	Phase 3		
Financial Funding Strategic Request	Licensing China and global rights, M&A, A-Round Financing		

Presentation Time: 1:45-2:00pm

No. MH1901	More Health-Access to the world's best healthcare		
Country	US	Project Classification	AI Medical Service
Project Phase	On market		
Financial Funding Strategic Request	Raise Total Amount \$30-50 Million Series D Fund.		

Presentation Time: 2:10-2:22pm

No. C1901	Innovative CART tech platforms		
Country	China	Project Classification	Biopharmaceuticals
Project Phase	Six CART products in clinical IRB		
Financial Funding Strategic Request			

Presentation Time: 2:22-2:34pm

No. C1902	Patient access platform for next generation clinical trials and disease management.		
Country	Belgium	Project Classification	AI
Project Phase			
Financial Funding Strategic Request	Strategic investment or exit		

Presentation Time: 2:34-2:46pm

No. C1903	US-China telehealth platform to assist Chinese health consumers/Pharma's global marketing		
Country	US, China	Project Classification	Digital Health/Access to Health
Project Phase	Commercialization with traction and revenues		
Financial Funding Strategic Request	Looking for Chinese strategic partners/investors; Financial funding A round.		

Presentation Time: 2:46-2:58pm

No. C1904	Universal Molecular Pharma Analytics workflow and consulting services for cell and gene therapy companies.		
Country	US	Project Classification	Biopharmaceuticals
Project Phase			
Financial Funding Strategic Request	Looking for a VC partner to expand operations in China and set up R&D facility in the US.		

Presentation Time: 2:58-3:10pm

No. C1905	Novel solution for storage and transport		
Country	US	Project Classification	Regenerative Medicine
Project Phase	Development for Drug Master File		
Financial Funding Strategic Request	Seeking visionary investment partners in our Series A financing.		

Presentation Time: 3:10-3:22pm

No. C1906	Portable blood test device		
Country	US	Project Classification	
Project Phase	Phase-II		
Financial Funding Strategic Request	Licensing in China and Global Right, strategic partnership, series-A		

Presentation Time: 3:22-3:34pm

No. C1907	Provide cutting edge microfluidics-based single cell technology for therapeutic antibody discovery, bispecific antibody screening and TCR/TCR antigen identification.		
Country	US	Project Classification	Antibody Therapeutics
Project Phase			
Financial Funding Strategic Request	Looking for A round financing and partnership.		

Presentation Time: 3:34-3:46pm

No. C1908	AI Based Hearing Aid		
Country	China	Project Classification	AI/hearing aid
Project Phase	POC/prototype completed, 1st version of software based hearing aid released.		
Financial Funding Strategic Request	Angel funding		

Presentation Time: 3:46-4:00pm

No. C1909	RNA+DNA combo liquid biopsy test		
Country	US, China	Project Classification	
Project Phase			
Financial Funding Strategic Request			

Presentation Time: 3:00-3:30pm(Parallel Roadshow, Room#410)

No. M1902	Antibody Radionuclide Conjugates (ARC)		
Country	Norway	Project Classification	Targeted Drug for Blood Cancer
Project Phase	Three products are currently in Phase I/II clinical trial stages.		
Financial Funding Strategic Request	<ul style="list-style-type: none"> · Actively looking for Chinese strategic partners and financial investors, open to license out China rights · Looking for partners to help conduct Phase III clinical trial in China 		

Presentation Time: 3:30-4:00pm(Parallel Roadshow, Room#410)

No. M1905	Innate Immune Checkpoint Inhibitor		
Country	US	Project Classification	Immuno-oncology
Project Phase	The combination with rituximab for non-Hodgkin's lymphoma and with cetuximab for colorectal cancer have entered Phase II stage of clinical trials, and the combination with Avelumab for ovarian cancer and the monotherapy for acute myeloid leukemia and solid tumors have entered Phase I clinical trials stage.		

Financial Funding Strategic Request	Explore the potential of finding strategic partners in China
--	--

Presentation Time: 4:00-4:20pm(Parallel Roadshow, Room#410)

No. E1916	Transformational immunotherapy platform		
Country	Canada	Project Classification	Biopharmaceuticals
Project Phase	Phase II		
Financial Funding Strategic Request	The company is raising USD \$10 million and is also seeking partnering and collaborations to further the development of SSIs.		

Presentation Time: 4:20-4:40pm(Parallel Roadshow, Room#410)

No. E1917	Bone Regenerative Medicine		
Country	US	Project Classification	Biopharmaceuticals
Project Phase	IND Submitted and Phase I clinical trial		
Financial Funding Strategic Request	Seeking to raise a \$30-\$40 million equity investment to drive RAB-001 through Phase II Clinical Trials in the US. Seeking partner(s) for a joint venture development for the RAB-series in China.		

Presentation Time: 4:00-4:30pm

No. M1904	New Generation Antibody Drug Conjugate (ADC)		
Country	US	Project Classification	Biologics
Project Phase	The drug has reached great clinical results in its early phase trials, and has the Phase III clinical trial conducting globally right now.		
Financial Funding Strategic Request	The company plans to find Chinese strategic partners and is open to license out the commercialization rights to the product in China.		

Presentation Time: 4:30-5:00pm

No. M1907	Visualization of T Cell Immune Responses Through Imaging		
Country	US	Project Classification	Immuno-imaging
Project Phase	The product has entered Phase II clinical trial		
Financial Funding Strategic Request	<ul style="list-style-type: none"> · Looking for a non-exclusive technology licensing agreement for partners' clinical research · Establish a standardized application process for CD8 immuno-PET with pharmaceutical companies, and establish and share the database · Looking for partners to develop small molecule antibodies for imaging and therapeutics 		

Presentation Time: 5:00-5:30pm

No. M1915 Harnessing the immune system to fight cancer

Presentation Time: 5:30-6:00pm

No. M1914	Oncology Diagnostic Imaging Platform		
Country	France	Project Classification	Oncology Diagnostics
Project Phase	Approved by FDA		
Financial Funding	The company plans to collaborate with cancer hospitals, diagnostic centers,		

Strategic Request	pharmaceutical companies and key opinion leaders in China in the fields of liver, lung, and prostate cancer, as well as nonalcoholic steatohepatitis (NASH) and immunooncology, and to collect clinical data.
-------------------	---

Presentation Time: 6:00-6:30pm

No. M1906	Cancer Vaccine		
Country	Canada	Project Classification	Therapeutic R&D
Project Phase	The cancer vaccine product has entered Phase II clinical trial. The anti-infection drug has also completed Phase I clinical trial		
Financial Funding	Actively looking for Chinese strategic partners to jointly develop the product in China		
Strategic Request	market through business cooperation or establishing a Joint Venture		

Other Selected Projects:

No. E1902	Universal Vaccines for the Prevention of Pneumococcal Infectious Disease		
Country	US	Project Classification	Biopharmaceuticals
Project Phase	Breakthrough Therapy (BT) Designation, expect on market in 2022.		
Financial Funding	A-Round Financing and Licensing China/Asia Rights		
Strategic Request			

No. E1904	Biosensor technology with solid-state CMOS chips		
Country	US	Project Classification	In Vitro Diagnostics
Project Phase	First product expected by Q2 2019.		
Financial Funding	Seeking development and commercialization partner for their biosensor technology.		
Strategic Request			

No. M1901	Novel Cellular Therapy for Oncology		
Country	Sweden	Project Classification	Therapeutic R&D
Project Phase	Lead product has entered Phase II clinical trial.		
Financial Funding	· Actively looking for Chinese strategic partners and financial investors, open to license out China rights		
Strategic Request	· Looking for partners to help conduct Phase III clinical trial in China		

No. M1903	Precise Genetic Editing Platform		
Country	US	Project Classification	Oncology Therapy, Gene Therapy
Project Phase	The CAR-T cellular therapy targeting CD19 has been approved for IND. Meanwhile, the company is developing CAR-T therapies for other targets.		
Financial Funding	The company is looking for strategic partners in China.		
Strategic Request			

No. M1908	Antibody-based Cancer Therapeutics		
Country	UK	Project Classification	Immuno-oncology
Project Phase	The company's ADC product has entered Phase I clinical trial		
Financial Funding	· Actively looking for Chinese strategic partners and financial investors		

Strategic Request	· Aim to raise US\$20-25M in China to further advance the research in check point inhibitors in immuno-oncology		
-------------------	---	--	--

No. M1909	High Sensitivity in Vitro Immunodiagnostic		
Country	US	Project Classification	In Vitro Diagnostics
Project Phase	The company's flagship product A has received CE certification in Europe and is on the market. Product A is currently awaiting FDA approval and is expected to launch the U.S. market in 2019		
Financial Funding Strategic Request	<ul style="list-style-type: none"> · Looking for Chinese strategic partners and distribution partners for Product A · Looking for Chinese strategic partners, manufacturing partners, and distribution partners for Product B · Open to Chinese equity investment or tech transfer for Product A and Product B. The company does not consider having a Joint Venture in China		

No. M1910	Treatment for Neurological Disorders		
Country	US	Project Classification	Neurology
Project Phase	The company has two underway Phase III clinical trials of the calcitonin gene-related peptide (CGRP) receptor antagonist research, and an NDA application for migraine treatment is expected in 2019		
Financial Funding Strategic Request	Actively looking for Chinese strategic partners		

No. M1911	Dry Eye Syndrome Relief and Anti-inflammation Analgesia After Eye Surgery		
Country	US	Project Classification	Ophthalmology
Project Phase	The product is the first and only FDA approved twice-daily ophthalmic corticosteroid. It has completed Phase II and Phase II clinical trials.		
Financial Funding Strategic Request	Actively looking for Chinese strategic partners		

No. M1912	Treatment for Alopecia Areata and Schizophrenia		
Country	US	Project Classification	Neurology
Project Phase	Clinical Trial Phase IIA		
Financial Funding Strategic Request	Actively looking for Chinese strategic partners		

No. M1913	Cooling Caps to Reduce Hair Loss After Chemotherapy		
Country	UK	Project Classification	Medical Device
Project Phase	On the market		
Financial Funding Strategic Request	Aim to launch the product in China in 2019		